BioSpace News Archive

Outlook Therapeutics, Inc. (NASDAQ: OTLK) (the “Company”), a late clinical-stage biopharmaceutical company working to develop the first FDA-approved ophthalmic formulation of bevacizumab for use in retinal indications, today announced that it has completed the previously announced warrant restructuring.

Prevail Therapeutics Inc. (Nasdaq: PRVL) (“Prevail” or the “Company”), a biotechnology company developing potentially disease-modifying AAV-based gene therapies for patients with neurodegenerative diseases, today announced that the U.S. Food and Drug Administration (FDA) has notified Prevail that the Company’s Investigational New Drug (IND) application for PR001 for the treatment of neuronopathic Gaucher disease (

Shinkowa Pharmaceutical Co., Ltd. (Head Office: Chuo Ward, Tokyo CEO: Megumi Tanaka) sells Nutraceuticals and cosmetics containing more than 99% high purity β-nicotinamide mononucleotide (hereinafter referred to as NMN) and conducts the world’s first human clinical researches.

ONCOLOGY PHARMA, INC. is pleased to announce that it has received a letter of intent dated December 20th to facilitate a financing of US$ 38.4 Million from SCP Investment Partners, Ltd, UK.

Astellas Pharma Inc. (TSE: 4503, President and CEO: Kenji Yasukawa, Ph.D., “Astellas”) and Xyphos Biosciences, Inc. (CEO: James Knighton, “Xyphos”) today announced that Astellas has acquired Xyphos.

Today, Lieutenant Governor Karyn Polito joined Massachusetts Life Sciences Center (MLSC) President and CEO Travis McCready, leaders from the Massachusetts Biomedical Initiatives (MBI), and state and local officials at the site of MBI’s expansion to celebrate construction progress of the redeveloped facility, which will double the operational capacity for the life sciences incubator.

On Dec. 23, 2019, at Seoul, South Korea, the CDMO segment of the world’s leading biotech company GenScript announced that it signed a strategic collaboration agreement with Selecxine Inc., a Korean biotech company dedicated to novel therapeutics for immuno-oncology

Can-Fite BioPharma Ltd. (NYSE American:CANF) (TASE:CFBI), a biotechnology company with a pipeline of proprietary small molecule drugs that bind specifically to the A3 adenosine receptor (A3AR), addressing cancer, liver and inflammatory diseases, announced today that Golan Bitton, CEO of Univo Pharmaceuticals (TASE:UNVO), was elected as a board member to Can-Fite at its recent annual general meeting.

The American Cancer Society (ACS) is widening its opportunities for participants in 2020 through the DetermiNation Endurance Series with the addition of events throughout the country

Immunomedics, Inc.(NASDAQ: IMMU) (“Immunomedics” or the “Company”), a leading biopharmaceutical company in the area of antibody-drug conjugates, today announced that the U.S. Food and Drug Administration (FDA) has accepted for filing the Company’s Biologics License Application (BLA) seeking accelerated approval of sacituzumab govitecan for the treatment of patients with metastatic triple-negative breast cancer